Expert Connect: Insights Into the Management of Treatment-Experienced Patients With SCLC
Small-cell lung cancer (SCLC) accounts for approximately 15% of lung cancers and is usually more aggressive than NSCLC. Until recently, few treatment options were available for SCLC, but recent approvals in the first- and second-line settings have advanced progression-free as well as overall survival in these patients. Unfortunately, while most patients with SCLC respond initially to first-line chemotherapy, almost all tumors recur, but response rates in the second-line setting are significantly lower. Within this CME activity, Dr. Jacob Sands evaluates the latest clinical evidence regarding the use of new and emerging options for the management of patients with SCLC who have progressed on first-line therapies as well as examines how these therapeutic options may address challenges and unmet needs in this patient population.
Cost: FreeView Offer chevron_right
- 0.5 AMA PRA Category 1 Credit(s)™
- 43% of activities take less than 30 minutes to complete
- The My Healio CME Dashboard keeps track of earned credits and saved activities
- Personalized recommendations make finding your next activity easy
- Over 50,000 of your colleagues know that earn credits is faster and easier with Healio CME
- Small-cell lung cancer (SCLS)
- Lung cancer
- First-line therapies
Upon successful completion of this educational activity, participants should be better able to:
-Assess the latest clinical evidence regarding the use of new or emerging options for the management of patients with SCLC who have progressed on chemotherapy.
-Examine how new and emerging options may address current challenges and unmet needs for patients with SCLC who have progressed on chemotherapy.
The intended audience for this activity is oncologists and other health care professionals involved in the management of patients with SCLC.
Additional credit info
This continuing medical education activity is provided by Vindico Medical Education
This activity is supported by an educational grant from Jazz Pharmaceuticals.
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, December 21, 2020, to December 20, 2021.